Merck Welireg Fails First-Line Kidney Cancer; Lilly's $7B Kelonia CAR-T

Merck's Welireg misses in first-line RCC — Cantor challenges $2B+ peak sales. Lilly buys Kelonia for up to $7B in in vivo CAR-T push. Medicare indefinitely delays GLP-1 weight loss drug coverage pilot. Plus AstraZeneca IgAN data, Roche MOGAD results, Arrowhead upgrade.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Merck, Welireg, belzutifan, kidney cancer, renal cell carcinoma, Keytruda, Lenvima, Eisai, Eli Lilly, Kelonia Therapeutics, CAR-T, cell therapy, in vivo, AstraZeneca, Ultomiris, IgA nephropathy, Roche, Enspryng, MOGAD, satralizumab, Medicare, GLP-1, weight loss, Foundayo, Wegovy, Novo Nordisk, Arrowhead Pharmaceuticals, Plozasiran, Pfizer, UCB, Neurona, Replimune, Idvynso, HIV, Kailera, Tortugas, Nektar, BioAge, Carvykti, Lilly, J&J